| WELL |
Report |
Normalized FFO per share (Q2 2026) |
BEAT |
pred ~$1.58 vs. cons $1.55 |
MEDIUM |
| WELL |
Report |
Total revenue (Q2 2026) |
BEAT |
pred ~$3.47B vs. cons $3.40B |
MEDIUM |
| WELL |
Report |
SHOP same-store NOI growth (Q2 2026) |
IN-LINE |
pred ~19.5% vs. cons ~19.8% |
LOW |
| WELL |
Guide |
FY2026 Normalized FFO per share guidance |
BETTER |
guide ~$6.40 vs. cons $6.32 (FY2026) |
MEDIUM |
| WELL |
Guide |
FY2026 SHOP same-store NOI growth guidance |
UNCHANGED |
guide ~17.5%-22.0% (~19.75% midpoint) vs. cons ~19.5% (FY2026) |
LOW |
| WELL |
Guide |
Year-end 2026 net debt/EBITDA leverage target |
UNCHANGED |
guide ~3.0x vs. cons ~3.0x (YE2026) |
MEDIUM |
| WELL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| WELL |
Return |
5-day cumulative residual |
-1.0% (STABILIZE) |
Stock is +34% YTD and near all-time highs into the print, with Street FFO already above the top of guidance ($6.32 vs $6.21-6.35), so a beat-and-raise is largely pre-priced (Q1's beat-and-raise only produced a -1.0% day-1 move followed by a flat week, vs. Q4's +1.8%/+9% follow-through off a lower base). Tougher H2 comps against 2025's record SHOP growth mean any FY raise likely just tracks consensus rather than surprising higher, capping upward revisions; but underlying occupancy/RevPOR fundamentals remain intact, so an initial soft/negative reaction should get partially bought back rather than extend into a deeper fade. |
LOW |